A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Ambu Announces: Ready to Launch its New Display Technology for Single-Use Endoscopy

Ambu announced today that the Ambu® aView™ 2 Advance has now obtained CE mark and is listed at Food and Drug Administration which enables release for sale in Europe and North America by mid-May 2020.

The aView 2 Advance is a portable full-HD display unit to be used together with our single-use endoscopes across multiple clinical specialties. Ambu, is a global manufacturer of medical devices, including single-use endoscopes.

“We have pioneered single-use endoscopy for more than ten years, and we now bring our portfolio to a new level of sophistication,” said Juan Jose Gonzalez, CEO of Ambu. “Image quality is critical for healthcare providers and patient diagnosis, and we can now offer a display unit that was not possible with a single-use endoscope just a few years ago. I believe we are raising the bar on innovative technology for hospitals and clinics.”

Jens Kemp, Ambu USA’s Vice President of Marketing said, the aView 2 Advance will fit the needs of clinicians throughout the hospital.

“Its mobile platform not only works well within the ICU, but specialists from other areas can use it to perform everything from cystoscopies to flexible laryngoscopies to bronchoscopies,” Kemp said. “It will increase workflow, efficiency and enable clinicians to address patients quickly.”

A reusable display for single-use devices

The aView 2 Advance is the display unit that clinicians connect a single-use scope into in order to transmit a live image from inside the human body. The scope is single-use and is discarded when the procedure is done – for hygienic, practical and economic reasons – while the display unit is reused as it has not been in contact with the patient.

“The aView 2 Advance seamlessly connects to the aScope family of sterile, single-use flexible endoscopes,” Kemp said. “A live image is displayed within seconds of powering on the monitor providing a high-quality image, with image capture and recording capability, in an easy to use, transportable monitor solution. After the procedure, health care providers can simply clean the monitor using commercially available disinfectant wipes widely used in healthcare.”

Technology for future product development

The aView 2 Advance covers Ambu’s existing endoscopes, which means that it can be used with a bronchoscope (for airway procedures), a rhinolaryngoscope (for ENT procedures) or a cystoscope (for urology procedures). The unit offers full-HD resolution, advanced image processing and an anti-reflective touchscreen. In addition, aView 2 Advance enables users to transfer recorded data to the hospital’s electronic health records (EHR).

The display unit is part of Ambu’s expansion across all major areas of endoscopy, and this technology platform will form the basis for the development of Ambu’s future single-use endoscope devices.

Built on a decade of experience

Ambu launched the world’s first single-use flexible bronchoscope, the Ambu® aScope™ in 2009. Ten years later, in 2019, over 600,000 Ambu single-use endoscopes were used in more than 3,500 hospitals making Ambu the world’s largest supplier of single-use endoscopes.

SourceAmbu
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy